Skip to main content

Key Factors Propelling the Growth in Influenza Vaccines Market 2023

 The influenza vaccines market in the United States was valued at US$ 3,962 million in 2022 and is expected to reach US$ 8,347 million by 2031, registering a CAGR of 8.6% during the forecast period.



Rapid market expansion is primarily due to increased research and development, the introduction of quadrivalent influenza vaccines, the aging population, and vaccine awareness. In addition, expanded recommendations from government and advisory bodies to get influenza vaccines are driving market growth in the United States.

Influenza is the second leading cause of death from vaccine-preventable disease in the United States after COVID-19. Rates of seasonal influenza infection are highest in children, but the risks for complications, hospitalizations, and deaths are higher in adults 65 years of age and older, children younger than 5 years, pregnant women, and people of any age with conditions that place them at increased risk for influenza complications.

The report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size, forecasts, and trends in the influenza vaccines market in the United States during 2018-2031. In addition, the report is a collective presentation of primary and secondary research findings.

Key Market Developments

  • The United States continues to be the world’s largest influenza vaccines market
  • Demand for influenza vaccines is expected to increase over the forecast period due to the pandemic COVID -19
  • Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate
  • Novavax announces initiation of Phase 2 study for COVID-19 influenza combination vaccine and stand-alone influenza vaccine candidate
  • GSK and CureVac advance mRNA COVID-19 and influenza vaccine candidates
  • Seqirus receives a government contract to develop 2 influenza vaccines

This Well-Versed and Comprehensive United States Influenza Vaccines Market Research Report 2023 is Divided into 20 Chapters:

  • Chapter 1 contains a brief description of the market under study
  • Chapter 2 describes the research methodology of the study
  • Chapter 3 identifies key trends and prospects for the U.S. influenza vaccine market and draws key conclusions
  • Chapter 4 discusses the market scenario for influenza vaccines in the United States in terms of historical market values and projections through 2031
  • Chapter 5 analysis of adults and children in the United States vaccinated with influenza vaccines and projection through 2031
  • Chapter 6 highlights key market dynamics in the U.S. influenza vaccine market, including factors driving the market, prevailing barriers, potential opportunities, and future trends. This section also includes an analysis of the impact of the driving and restraining factors
  • Chapter 7 offers comprehensive insights into the latest pricing trends and analysis of the U.S. influenza vaccine market
  • Chapter 8 includes a comprehensive analysis of influenza vaccine production, supply, and distribution in the United States (by company)
  • Chapter 9 provides a complete overview of influenza vaccine distribution and demand in the United States
  • Chapter 10 investigates the effectiveness of influenza vaccines in the United States
  • Chapter 11 thorough evaluation of rapid diagnostic tests for influenza management
  • Chapter 12 carefully evaluates the distribution channel and technique of influenza vaccination in the United States
  • Chapter 13 characteristics of reimbursement structures in the influenza vaccine market in the united states
  • Chapter 14 detailed insights into the legal framework of the U.S. influenza vaccine market
  • Chapter 15 tracks competitive developments, approaches, recent industry developments, and mergers and acquisitions, collaboration, distribution, exclusivity, and licensing agreements.
  • Chapter 16 an informative study was conducted on promising influenza vaccines in clinical development.
  • Chapter 17 analyses recent clinical trials of the influenza vaccine
  • Chapter 18 and 19 provides the industry landscape and detailed profiles of key and promising companies operating in the influenza vaccine market in the United States. The companies have been profiled based on their key facts, business description, products and services, current vaccine portfolio, promising vaccines in clinical development, platform technology, and key developments.
  • Chapter 20, i.e. the appendix contains a brief overview of the company, a glossary, contact information, and the disclaimer section.

Key and Emerging Players in the U.S. Influenza Vaccines Market are Listed Below:

  • Sanofi Pasteur
  • GlaxoSmithKline (GSK)
  • Seqirus (CSL Limited)
  • AstraZeneca
  • Novavax
  • Medicago
  • Moderna Inc
  • Pneumagen
  • Daiichi–Sankyo
  • Altimmune
  • FluGen
  • Imutex
  • EpiVax, Inc
  • Versatope Therapeutics, Inc
  • BiondVax Pharmaceuticals Ltd.

The Most Important Questions are Answered in this Current 2023 Report:

  • What is the current size of the U.S. influenza vaccine market?
  • What will be the CAGR of the influenza vaccine market in the United States?
  • How many people will be vaccinated with flu vaccines in the U.S. between 2018 and 2031?
  • What percentage of people in the United States get vaccinated against influenza?
  • What are the main flu vaccines available in the United States?
  • What are the key drivers of the influenza vaccine market in the United States?
  • What are the major barriers to the influenza vaccine market in the United States?
  • What is the reimbursement pattern in the influenza vaccine market in the United States?
  • What is the regulatory framework for the influenza vaccine market in the United States?
  • What are the key deals and agreements in the United States influenza vaccine market?
  • What are the upcoming flu vaccines that will significantly impact the market in the future?
  • Who are the main market participants? What is happening with them, what revenues do they generate from vaccines, and what are the current developments and scenarios?
  • Who are the new players? What are their events, clinical developments, platform technologies, phases, and current developments?
  • How is the market likely to develop in the future?

Get Free Copy of Market Research Reports @ https://dpiresearch.com/reports/united-states-influenza-vaccines-market-2023/

Comments

Popular posts from this blog

At 18% CAGR, U S NIPT Test Market Size is Expected to Exhibit US$ 2 2 b...

GCC Countries will Attract 7.7 Million Indian travelers by 2025

  According to the DPI Research new growth forecast report titled  Impact of the COVID-19 Outbreak on Indian Outbound Travelers Traffic and Market Revenue to the GCC Countries   Value is set to earn USD 12 billion by 2025. It is forecasted that GCC countries will attract nearly 7.7 Million Indian travelers and generated more than US$ 12 billion market revenues by 2025. The objective of this market research report is to provide an overview of the development of the Indian outbound travelers traffic to the major continents and to give an insight into the Indian outbound travelers’ traffic and market revenue to the GCC countries. The GCC Countries which we covered in the report are UAE, Saudi Arabia, Oman, Qatar, Kuwait, and Bahrain. The database of the following report is defined as follows: Total India Outbound Travelers Visitation & Forecast – By Continents (2018 – 2025) India Outbound Travelers Visitation to the GCC Countries & Forecast (2018 – 2025) India Outbound Travelers M

Global Influenza Vaccines Market Prospects and Growth Potential

  The global influenza vaccines marke t size was valued at USD 7.8 Billion in 2023 and is likely to reach USD 13.7 Billion in 2032, expanding at a CAGR 7.2% during the forecast period.